

NUTRA PHARMA CORP
Form SC 13D
June 29, 2018

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a)**

(Amendment No. _____)*

NUTRA PHARMA CORP

(Name of Issuer)

Common Stock

(Title of Class of Securities)

67060U208

(CUSIP Number)

Rik J. Deitsch

12538 W. Atlantic Blvd.

Edgar Filing: NUTRA PHARMA CORP - Form SC 13D

Coral Springs, FL 33071

(954) 509-0911

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 30, 2017

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* § 240.13d-7 for other parties to whom copies are to be sent.

- * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*.)

CUSIP No. 67060U208

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

2. Rik. J. Deitsch
Check the Appropriate Box if a Member of a Group (See Instructions)

(a) (b)

3. SEC Use Only

4. Source of Funds

5. PF
Check Box if Disclosure of Legal Proceeding is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

Number of	7.	Sole Voting Power
Shares		
Beneficially	8.	3,043,298,859
owned by		Shared Voting Power
Each		0
Reporting	9.	Sole Dispositive Power
Person		
With:	10.	3,043,298,859
		Shared Dispositive Power

0

11. Aggregate Amount Beneficially Owned by Each Reporting Person

3,043,298,859

12. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

13. Percent of Class Represented by Amount in Row (11)

57%

14. Type of Reporting Person (See Instructions)

IN

Item 1. Security and Issuer

This statement relates to the Common Stock, \$0.001 par value (Common Stock) of the Issuer, Nutra Pharma Corp. (Nutra Pharma or the Issuer). The principal executive offices of the Issuer are presently located at 12538 Atlantic Blvd., Coral Springs, Florida 33071. The Reporting Person is the owner of 3,000,000 shares Series A Preferred Stock; \$0.001 par value of the Issuer which votes with the Common Stock at a rate of 1,000 common shares to 1 preferred share.

Item 2. Identity and Background

(a)

This statement is filed by Rik. J. Deitsch.

(b)

Business Address:

12538 W. Atlantic Blvd.
Coral Springs, FL 33071

(c)

The principal business of Rik J. Deitsch is acting as Chief Executive Officer of Nutra Pharma Corporation.

(d)

During the last five (5) years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)

During the past five years, the Reporting Person (a) has not been convicted in a criminal proceeding or (b) has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of which has not been subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

(f)

Citizenship: United States Citizen

Item 3. Source and Amount of Funds or Other Consideration

Corporate loan repayment

Item 4. Purpose of Transaction

The purpose of the October 30, 2017 transaction was to discharge corporate debt owed to the Reporting Person in exchange for Series A Preferred Stock.

Item 5. Interest in Securities of the Issuer

As of June 28, 2018, the aggregate number and percentage of class of securities identified pursuant to Item 1 beneficially owned by each person named in Item 2 may be found in rows 11 and 13 of the cover pages.

The powers of the Reporting Person identified in the preceding paragraph has relative to the shares discussed herein may be found in rows 7 through 10 of the cover pages.

No transactions in the class of securities reported on were effected by any of the persons named in this Item 5 during the past 60 days.

Item 6. Contracts, Arrangements, Understandings or Relationships with respect to the Securities of the Issuer.

Except as set forth elsewhere in this Schedule 13D, there are no contracts, arrangements, understandings or relationships among the Persons named in Item 2 and between such persons and any other person with respect to any securities of the Issuer, including but not limited to the transfer of voting of any securities, finder's fees, joint ventures, loan or option agreements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

Item 7. Material to be Filed as Exhibits.

None

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: June 29, 2018

By:	/s/ Rik. J. Deitsch
Name:	Rik. J. Deitsch
Title:	Individual